Defibrillation Lead Exceeds Expectations in Clinical Trial

BOSTON — An investigative small-diameter defibrillation lead for implantable cardioverter-defibrillators has exceeded its safety and efficacy expectations in a pivotal clinical trial. The LEADR trial implanted OmniaSecure leads in 643 patients. It found that almost 98% of the experimental leads were successfully implanted, and 99.5% were placed precisely in the desired location in the right …

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button